Shubham Pant, MD, MBBS

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Shubham Pant, MD, MBBS, discusses the rationale for the phase 2b HERIZON-BTC-01 trial and shares the results with zanidatamab in previously treated HER2-amplified biliary tract cancer.

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.